SpringWorks Therapeutics
SWTX
SWTX was delisted on the 30th of June, 2025.
306 hedge funds and large institutions have $3.29B invested in SpringWorks Therapeutics in 2025 Q1 according to their latest regulatory filings, with 113 funds opening new positions, 85 increasing their positions, 86 reducing their positions, and 22 closing their positions.
414% more first-time investments, than exits
New positions opened: 113 | Existing positions closed: 22
141% more call options, than puts
Call options by funds: $287M | Put options by funds: $119M
42% more funds holding
Funds holding: 216 → 306 (+90)
29% more funds holding in top 10
Funds holding in top 10: 7 → 9 (+2)
13% more capital invested
Capital invested by funds: $2.92B → $3.29B (+$368M)
1% less repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 86
9.3% less ownership
Funds ownership: 108.76% → 99.46% (-9.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$58.7M |
| 2 |
Barclays
London,
United Kingdom
|
+$35.6M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$30.1M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$29.8M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$24.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$125M |
| 2 |
BCM
Boxer Capital Management
San Diego,
California
|
-$124M |
| 3 |
MC
Maverick Capital
Dallas,
Texas
|
-$112M |
| 4 |
Capital International Investors
Los Angeles,
California
|
-$107M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
-$56.4M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
QCG
326
Quadrant Capital Group
Cincinnati,
Ohio
| – | -$3.61K | -100 | Closed |
|
|
JFGIW
327
Johnson Financial Group Inc (Wisconsin)
Racine,
Wisconsin
| – | -$2.81K | -75 | Closed |
|
328
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$1.26K | -35 | Closed |
|
SWTX Hedge Fund Activity: Q1 2025 in Review
306 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in SpringWorks Therapeutics (SWTX) for Q1 2025, worth a combined $3.29B — up 13% from $2.92B a quarter earlier.
Buyers outnumbered sellers: 113 funds opened new SWTX positions and 22 closed out — a net gain of 91 holders — while 85 added to existing stakes and 86 trimmed.
The largest buyer was D.E. Shaw & Co, adding an estimated $58.7M. The largest seller was Deep Track Capital, exiting entirely with an estimated $125M sold.
- 306 institutional investors held SpringWorks Therapeutics (SWTX) as of Q1 2025, up from 216 in Q4 2024.
- Funds reported $3.29B of SpringWorks Therapeutics stock for Q1 2025, up 13% quarter-over-quarter.
- 113 funds opened new SpringWorks Therapeutics positions in Q1 2025 and 22 closed out, a net change of +91 holders.
- The largest SpringWorks Therapeutics buyer in Q1 2025 was D.E. Shaw & Co, an estimated $58.7M added.
- The largest SpringWorks Therapeutics seller in Q1 2025 was Deep Track Capital, an estimated $125M sold.
Based on aggregated 13F filings for Q1 2025.